Robert Wasserman
Stock Analyst at Benchmark
(3.38)
# 976
Out of 4,711 analysts
109
Total ratings
48.42%
Success rate
3.29%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $27.39 | +9.53% | 6 | Dec 19, 2024 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $0.99 | +708.08% | 6 | Nov 19, 2024 | |
| OABI OmniAb | Reiterates: Buy | $8 | $3.50 | +128.57% | 7 | Nov 14, 2024 | |
| NEPH Nephros | Reiterates: Speculative Buy | $5 | $1.54 | +224.68% | 3 | Nov 12, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $110 → $135 | $114.64 | +17.76% | 9 | Nov 8, 2024 | |
| EBS Emergent BioSolutions | Maintains: Buy | $8 → $12 | $8.10 | +48.15% | 17 | Nov 7, 2024 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $2.85 | - | 5 | Nov 5, 2024 | |
| CDXS Codexis | Reiterates: Hold | n/a | $5.28 | - | 7 | Nov 4, 2024 | |
| ITGR Integer Holdings | Reiterates: Buy | $140 | $133.67 | +4.74% | 9 | Oct 25, 2024 | |
| IPA ImmunoPrecise Antibodies | Maintains: Speculative Buy | $5 → $3 | $0.40 | +649.81% | 5 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $73.17 | +29.83% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $46.96 | +27.77% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $144.46 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $12 | $1.88 | +538.30% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $40.72 | +10.51% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $2.20 | +81.82% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.85 | +370.59% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $1.72 | +4,260.47% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $228.55 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $524.05 | +10.68% | 1 | Jul 16, 2021 |
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $27.39
Upside: +9.53%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $0.99
Upside: +708.08%
OmniAb
Nov 14, 2024
Reiterates: Buy
Price Target: $8
Current: $3.50
Upside: +128.57%
Nephros
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $1.54
Upside: +224.68%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Buy
Price Target: $110 → $135
Current: $114.64
Upside: +17.76%
Emergent BioSolutions
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $8.10
Upside: +48.15%
AbCellera Biologics
Nov 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.85
Upside: -
Codexis
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $5.28
Upside: -
Integer Holdings
Oct 25, 2024
Reiterates: Buy
Price Target: $140
Current: $133.67
Upside: +4.74%
ImmunoPrecise Antibodies
Aug 14, 2024
Maintains: Speculative Buy
Price Target: $5 → $3
Current: $0.40
Upside: +649.81%
Aug 13, 2024
Reiterates: Buy
Price Target: $95
Current: $73.17
Upside: +29.83%
Aug 8, 2024
Reiterates: Buy
Price Target: $60
Current: $46.96
Upside: +27.77%
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $144.46
Upside: -
Jul 11, 2024
Reiterates: Speculative Buy
Price Target: $12
Current: $1.88
Upside: +538.30%
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $40.72
Upside: +10.51%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $2.20
Upside: +81.82%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.85
Upside: +370.59%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $1.72
Upside: +4,260.47%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $228.55
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $524.05
Upside: +10.68%